Development, Feasibility and Effectiveness of a Digital Support Platform for Mental Health in Primary Care (PRESTO). (PRESTO)
Depression, Anxiety

About this trial
This is an interventional treatment trial for Depression, Anxiety focused on measuring PRESTO, smartphone, application, primary care, anxiety, depression
Eligibility Criteria
Inclusion criteria:
- Individuals 18-65 years of age who are referred to or are being followed up by members of the PCMHSP in the 5 PCCs corresponding to the 5 Barcelona catchment areas (ABS).
- Scoring between 4 and 14 points on the PHQ-9 scale, or 6 to 15 on the GAD-7 scale.
- They must also accept and sign the informed consent for study participation and must have a compatible smartphone (Android or iPhone).
Exclusion criteria:
- Individuals who do not know and/or do not wish to learn the skills required to operate a smartphone.
- Estimated IQ less than 70 with functional impairment Patients with severe mental disorder (Bipolar Disorder, Schizophrenic Disorder, Schizoaffective, Obsessive-Compulsive) or substance use disorder.
- PHQ-9 >= 15
- GAD-7 >= 16.
- People with moderate to severe suicidal ideation (PHQ-9 Question 9 with a score of 2 or 3)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Active group - PRESTOapp users
Control group
Once users are recruited, an independent researcher will randomize the participants using a 1:1 sequential method in two groups of 76 individuals and will assign a 6-digit identification code (IC) to each participant. The IC will be given to the participant on a reminder card and will be used to access the app guaranteeing its confidentiality. The name of the subjects and their respective code will be stored in independent servers for methodological, security and legal reasons. The intervention group will be asked to use the app for a period of 2 months. The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.